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Abstract
Objective: Tourette Syndrome is polygenic and highly heritable. Genome-wide association 
(GWAS) approaches are useful for interrogating the genetic architecture and determinants of 
Tourette syndrome and other tic disorders.
Method: GWAS meta-analysis, gene-based association, and genetic enrichment analyses were 
conducted in 4,819 Tourette syndrome cases and 9,488 controls. Replication of top loci was 
conducted in an independent, population-based sample (706 cases; 6,068 controls). Relationships 
between Tourette polygenic risk scores (PRS), other tic disorders, ascertainment, and tic severity 
were examined.
Results: GWAS and gene-based analyses identified one genome-wide significant locus within 
FLT3 on chromosome 13, rs2504235 (SNP p=2.1×10−8; Gene p=8.9×10−7), though this 
association was not replicated in the population-based sample. Genetic variants spanning 
evolutionarily-conserved regions explained 92.4% of Tourette syndrome heritability (Bonferroni 
corrected p-value=0.005). Tourette-associated genes were preferentially expressed in human 
dorsolateral prefrontal cortex (p=1.2×10−4). Tourette PRS predicted both Tourette syndrome 
(p=5.3×10−9) and tic spectrum disorders (p=4.2 ×10−4) status in the population-based sample. 
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Tourette PRS also correlated with worst-ever tic severity (p=0.026) and was higher in cases with a 
family history of tics than in simplex cases.
Conclusions: Modulation of gene expression through non-coding variants, particularly within 
cortico-striatal circuits, is implicated as a fundamental mechanism in Tourette syndrome 
pathogenesis. At a genetic level, tic disorders represent a continuous spectrum of disease, 
supporting the unification of Tourette syndrome and other tic disorders in future diagnostic 
schema. Tourette PRS derived from sufficiently large samples may be useful in the future for 
predicting conversion of transient tics to chronic tic disorders, as well as tic persistence and 
lifetime tic severity.
INTRODUCTION
Tourette syndrome is a complex neuropsychiatric disorder that occurs along a phenotypic 
spectrum that also includes chronic (persistent) motor or vocal tic disorder (chronic tics) and 
transient (provisional) tic disorder (1). Although Tourette syndrome is highly heritable (2), 
variants in known Tourette risk genes (e.g., CNTN6, NRXN1, SLITRK1, HDC, and 
CELSR3) account for fewer than 2% of affected individuals (3–6). Tourette syndrome is 
highly polygenic, with a demonstrated role for multiple common genetic variants of small 
effect distributed widely across the genome (7). Thus, genome-wide association studies (8) 
will be of benefit in further elucidating its underlying genetic etiology.
To date, only one Tourette GWAS has been published (9). Although no single nucleotide 
polymorphisms (SNPs) met criteria for genome-wide significance (p<5×10−8), in aggregate, 
the top SNPs (p-values <1×10−3) were enriched for expression quantitative trait loci 
(eQTLs) in frontal cortex and for methylation quantitative trait loci (mQTLs) in the 
cerebellum, indicating that a significant proportion of these variants have biological 
relevance to Tourette syndrome, and perhaps also to other tic disorders. However, as with 
other neuropsychiatric disorders, much larger sample sizes are needed to elucidate the 
disorder’s genetic underpinnings. Here, we report the results of a GWAS meta-analysis from 
the Psychiatric Genomics Consortium (PGC) Tourette Syndrome Workgroup in a sample 
that is nearly four times larger than the initial GWAS. We also probe aggregated Tourette 
syndrome polygenic risk to test two specific hypotheses: 1) whether Tourette and related tic 
disorders have an underlying shared genetic etiology; and 2) whether Tourette polygenic risk 
scores correlate with worst-ever tic severity and might represent a future potential predictor 
of disease severity.
METHOD
Subjects
The primary GWAS meta-analysis consisted of four European ancestry (EU) GWAS 
datasets: 1) 969 cases and 3,923 ancestry-matched controls from the initial Tourette 
syndrome GWAS (GWAS1) (9); 2) 2,711 additional EU ancestry Tourette cases (4) and 
3,762 ancestry-matched controls (GWAS2); 3) Tourette probands from GWAS1 and one or 
more of their Tourette syndrome-affected family members (10) (N=548) plus 597 ancestry-
matched controls (GWAS2 FAM); 4) 591 independent EU Tourette probands from the TIC 
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Genetics consortium (TIC)(11) and 1,206 unselected ancestry-matched controls. Genotyping 
details are provided in the online Data Supplement (Tables S1 and S2).
GWAS1: 969 EU cases were collected from Tourette syndrome specialty clinics in the US, 
Canada, the UK, the Netherlands, and via recruitment from the Tourette Association of 
America membership. Tourette diagnoses were assigned based on DSM-IV-TR criteria plus 
observation of tics by an experienced clinician. 3,923 controls were identified primarily 
from previously genotyped unselected population controls and ancestry matched to the cases 
(9).
GWAS2: 2,871 EU cases with DSM-5 Tourette syndrome were identified by email/online 
recruitment combined with validated, web-based phenotypic assessments (12, 13) 
(N=1,264), or from Tourette syndrome specialty clinics in the US, Canada, and Europe 
(N=1,607) (Supplemental Methods). All subjects were genotyped at the UCLA 
Neuroscience Genomics Core (UNGC). After quality control, 2,711 cases were retained for 
analysis.
GWAS2 FAM: The family sample consisted of 548 probands and first-degree relatives with 
Tourette syndrome from 207 independent families(10). 175 probands came from the original 
Tourette GWAS1 sample; these cases were removed from the GWAS1 analysis along with 
ancestry-matched controls and re-analyzed with the family-based sample. 32 Tourette 
probands and 341 additional Tourette-affected family members (total N=373) were 
genotyped along with the GWAS2 case-control sample. 597 ancestry-matched controls were 
selected from a pool of previously genotyped controls (Supplemental Methods).
TIC: The TIC Genetics sample consisted of 591 probands, 579 who met DSM-5 criteria for 
Tourette syndrome, and 12 with DSM-5 chronic motor or vocal tic disorder (Table S1, S2).
Controls: 6,920 EU controls were obtained from cohorts of previously genotyped, 
unselected population controls for the GWAS2 analyses; an additional 595 EU controls were 
genotyped with the Tourette cases at the UNGC (Table S1; Supplemental Methods).
deCODE: An independent case-control replication sample from Iceland (deCODE genetics, 
Reykjavik, Iceland) consisted of 706 Icelandic Tourette syndrome cases and 466 cases with 
other tic disorders (chronic tics or unspecified tic disorder) (Supplemental Methods). 
127,164 unscreened population-matched controls were also available; 6,068 of these were 
screened and reported no lifetime subclinical motor or vocal tics. Cases and controls were 
genotyped at deCODE on Illumina SNP arrays (Supplemental Methods).
Participants ages 18 years and older provided written informed consent. Individuals under 18 
gave assent; parental permission was also obtained. The study was approved by the human 
subjects committees at all participating sites.
Quality Control
Genotyping quality control was performed in PLINK v1.9 (14) (Supplemental Methods). 
Duplicates and relatives were identified using genome-wide identity-by-descent estimates, 
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and one member of each duplicate or relative pair was removed from the case-control 
sample. Relative pairs where both individuals had a Tourette diagnosis were removed from 
the case-control sample and moved to the family-based analysis.
Population stratification was assessed through multidimensional scaling (MDS) analysis; 
individuals of non-European ancestry and extreme outliers on each of the MDS components 
were removed (Supplemental Methods and Figure S1). Case-control matching was verified 
across all MDS components. The final post-quality control GWAS2 sample contained 2,711 
cases and 3,762 ancestry-matched controls and 550,550 SNPs; the final GWAS2 FAM 
sample contained 548 cases/family members, 597 ancestry-matched controls and 236,748 
SNPs. The final TIC sample included 591 cases and 1206 ancestry-matched controls and 
581,774 SNPs (Table S2).
Imputation and Genome-wide Association
SNP imputation was conducted on all genotype data for the primary meta-analyses using the 
1000 Genomes Project Phase 1 integrated haplotypes (December 2013 release, with 
singleton sites removed) as the reference panel (15). ShapeIT was used to phase genotype 
data, followed by imputation with IMPUTE v2. SNPs with Information score <0.6 or 
Certainty <0.9 were excluded.
Genome-wide association tests were performed on the imputed dosage data of GWAS2 and 
TIC samples separately in PLINK1.9, using logistic regression under an additive model with 
the first four MDS components and any additional MDS components associated with 
Tourette case-control status at p<0.05 included as covariates. A linear mixed model was used 
for the GWAS2 FAM association analysis in MMM v.1.0 (16) to control for familial 
relatedness. GWAS1 samples were re-imputed as described above; association tests were 
performed in four ancestry-based strata: Non-isolate European (GWAS1_EU), Ashkenazi 
Jewish (GWAS1_AJ), French Canadian (GWAS1_FC), and GWAS1 TIC (GWAS1_TIC) 
(Table S2).
A primary GWAS meta-analysis was conducted on the GWAS1, GWAS2, GWAS2 FAM, 
and TIC datasets using the inverse-variance method in METAL (17). Heterogeneity was 
assessed with Cochran’s I2 statistics. The genomic control factor (λ) was calculated for each 
individual GWAS and for the overall meta-analysis using all SNPs with MAF>0.01 to 
identify residual population stratification or systematic technical artifact (Figure S2). GWAS 
summary statistics were subjected to linkage disequilibrium (LD) score regression (LDSC) 
analyses on high quality, common SNPs (INFO>0.9 and MAF>0.01) to examine the LDSC 
intercept as a more specific measure of inflation of the GWAS test statistic (18) due to 
residual artifact or stratification. The genome-wide significant threshold for the GWAS (19, 
20) was set at p=5.0×10−8.
Heritability Estimation
Tourette syndrome SNP-based heritability was estimated on the liability scale, assuming a 
population prevalence of 0.8% (21), using both LDSC (18) and, in GWAS1 and GWAS2 
samples after excluding Ashkenazi Jewish samples, using genotype-level data in a linear 
mixed model framework (7). To compare the relative polygenic burden of Tourette syndrome 
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samples collected with different ascertainment methods, the Tourette GWAS1 and GWAS2 
datasets were separated into 3 groups: 1) GWAS1 cases (25% from affected sib-pair 
families)(10); 2) GWAS2 cases recruited through Tourette syndrome specialty clinics; 3) 
GWAS2 cases recruited via email from the membership of the Tourette Association of 
America and assessed with a web-based phenotyping instrument (12). Following additional 
stringent quality control of SNPs and samples (Supplemental Methods), the SNP-based 
heritability of each ascertainment group was estimated both separately and jointly.
Partitioned heritability analyses were conducted using LDSC to evaluate enrichment of 
Tourette SNP-based heritability from different functional annotation classes and different 
cell/ tissue types (22) and to examine genetic correlations between the GWAS1, GWAS2, 
and TIC datasets.
Targeted Replication
The population-based deCODE samples were used to: 1) independently replicate the 39 top 
LD-independent SNPs (r2<0.2 and MAF>0.01; p<1.0×10−5) in the primary meta-analysis, 
followed by a sign test to examine consistency in the direction of effects in these top SNPs 
across the two datasets, as well as a targeted meta-analysis of these 39 SNPs using the 
inverse-variance method (Supplemental Methods); and 2) examine the genetic relationships 
between Tourette and other tic disorders through polygenic risk score (PRS) analyses 
(Supplemental Methods) (23). Logistic regressions were performed to test the prediction 
power of PRS for Tourette syndrome and tic disorders cases versus controls, adjusted by sex, 
year of birth, and the first 20 principal components (24).
Polygenic Risk Score Analyses
Genome-wide Tourette PRS adjusted for ancestry principal components (aPRS) were 
generated for all subjects in the primary meta-analysis using the entire distribution (GWAS 
p≤1) of LD-independent SNPs (r2<0.2) through a cross-validation approach (23) and used to 
examine the relationship between Tourette aPRS and ascertainment, family history of 
Tourette/ chronic tics, and lifetime worst-ever tic severity (Yale Global Tic Severity Scale 
Total Tic Score (tic severity), range 0-50) (Supplemental Methods).
Gene-based and Gene Set Enrichment Analysis
Gene-based and competitive gene set enrichment analyses were conducted in MAGMA (25) 
(Supplemental Methods). Gene-based test statistics were derived using association summary 
statistics for all SNPs assigned to each gene including 50kb flanking regions after 
accounting for LD. P-values were adjusted with a Bonferroni correction for 18,079 genes 
genome-wide. Gene-based statistics were then analyzed for tissue expression enrichment in 
53 distinct human tissues from 714 donors using GTEx RNA-seq data (26), and Bonferroni 
correction was applied for 53 tissue types (p=0.05/53=9.4×10−4). Tested gene sets included 
107 probable autism spectrum disorder susceptibility genes from exome sequencing studies 
(27), evolutionarily constrained genes (probability of Loss-of-Function Intolerance (pLI) 
score >0.9), previously identified constrained genes harboring deleterious rare variants (large 
CNVs or de novo loss of function mutations) in Tourette syndrome cases (4, 5), and all Gene 
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Ontology terms from MSigDB6.0 (Supplemental Methods). Bonferroni correction was 
applied for the number of gene sets tested.
RESULTS
Genome-wide Association Study
The final GWAS meta-analysis consisted of 8,265,319 SNPs in 4,819 Tourette syndrome 
cases and 9,488 controls. No evidence for residual population stratification or systematic 
technical artifact was observed in any of the individual datasets (Figure S2) or in the final 
meta-analysis (λ=1.072, λ1000=1.011, Figure 1). LDSC indicated that 86% of the observed 
test statistic inflation was attributable to an underlying genome-wide polygenic signal 
(Figure S3). PRS analyses in each individual GWAS dataset derived using a “leave one out” 
approach, and in the deCODE sample, indicated genetic homogeneity across all contributing 
datasets (Figures S4 and S5).
The top SNP in the GWAS meta-analysis, rs2504235, located on chromosome 13q12.2, 
surpassed the genome-wide significance threshold (OR=1.16, p=2.1×10−8, Table 1; Figure 
S6). rs2504235 lies within an intron of FLT3, encoding FMS-like tyrosine kinase 3. No 
other SNPs achieved genome-wide significance, although rs1933437, a common FLT3 
missense variant (Thr227Met) that lies 11.4 kb away from and is in strong LD with 
rs2504235 (r2=0.93), had a p-value of p=8.2×10−8 (Table S3). Across the genome, 39 LD-
independent index SNPs with p<1×10−5 were identified by LD pruning (r2<0.2) followed by 
conditional association analyses controlling for the most significant SNP within each 2 Mb 
window and manual inspection of regional association plots to confirm the presence of 
supporting statistical evidence of association from nearby SNPs (Tables S3 and S4). The top 
10 LD-independent index SNPs are presented in Table 1.
Targeted Replication
The 39 LD-independent index SNPs with p<1×10−5 were investigated for replication in the 
deCODE sample (706 cases, 6,068 controls). None of the individual SNPs were replicated 
after Bonferroni correction (replication threshold for 39 tests, p<0.0013; Table 1; Table S4); 
23 of 39 putative Tourette syndrome risk alleles had the same direction of effect, though this 
was not statistically significant (Binomial two-way sign test, p=0.34).
Meta-analysis restricted to these 39 SNPs was conducted using summary statistics from the 
primary meta-analysis and the deCODE data with the inverse variance method in METAL. 
No SNPs achieved genome-wide significance; the SNP with the lowest p-value was 
rs13407215 on chromosome 2 (p=1.9×10−7). rs2504235 was not genome-wide significant in 
this analysis (p=2.4×10−7) (Table 1, Table S4).
Heritability and Polygenic Risk Score Analyses
Tourette syndrome SNP-based heritability (h2g) was estimated in the primary GWAS meta-
analysis using LDSC (h2g=0.21, SE=0.024, p<2.0×10−16). Pairwise genetic correlations 
across the three independent case-control datasets (GWAS1, GWAS2, TIC) confirmed a 
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significant, shared polygenic architecture (rgGWAS1-GWAS2=0.86 (SE=0.21), p=3.9×10−5; 
rgGWAS1-TIC=0.84 (SE=0.30), p=4.5×10−3; rgGWAS2-TIC=0.93 (SE=0.26), p=4×10−4).
As the previous estimate of Tourette syndrome h2g from the first Tourette GWAS 
(h2g LMM=0.58, SE=0.09) (7) was significantly higher than that observed in this study, 
additional heritability analyses were conducted in the individual datasets stratified on 
ascertainment status using linear mixed models (LMM)(7) (Table 2). These analyses 
confirmed both the high SNP-based heritability of the sib-pair enriched Tourette GWAS1 
sample (h2g GWAS1-LMM=0.56, SE=0.10; p=1.2×10−9), and the lower heritability of the 
larger GWAS2 sample (h2g GWAS2-LMM=0.29, SE=0.04; p=5.5×10−14).
To explore the hypothesis that the lower heritability of the Tourette GWAS2 sample might 
have arisen from the inclusion of Tourette cases diagnosed in the community and ascertained 
using a validated web-based screen (12, 13), the GWAS2 case-control sample was divided 
into clinic-based cases vs. web-based cases, and the LMM-based heritability analyses were 
repeated. Contrary to the predicted hypothesis, both subsets had the same heritability 
(h2g GWAS2-clinic=0.29, SE=0.07; p=1.2×10−9; h2g GWAS2-web=0.28, SE=0.10; p=1.2×10−9) 
(Table 2).
Tourette syndrome PRS in Multiplex vs. Simplex Families
Since a large proportion of Tourette GWAS1 cases were derived from affected sib-pair 
families, which might be expected to harbor higher Tourette syndrome polygenic risk than 
cases from simplex families without affected first-degree relatives, we examined the 
relationship between ancestry-adjusted PRS (aPRS) in cases from multiplex (first-degree 
relative family-history positive) versus simplex (first-degree relative family-history negative) 
families (Supplemental Methods).
As multiplex Tourette syndrome cases with a Tourette-affected parent or sibling (N=417) 
demonstrated similar mean aPRS to Tourette GWAS cases with a chronic tic-affected parent/
sibling (N=111) (Fdf=1=0.12, p=0.73), we combined both Tourette case groups together for 
further analyses (Tourette/chronic tic family-history positive cases, N=528). The combined 
Tourette/ chronic tic multiplex cases had a significantly increased mean aPRS compared to 
aPRS from Tourette/ chronic tic simplex cases (N=346) (Fdf=1=4.90, p=0.027), confirming 
that multiplex cases were enriched for Tourette polygenic risk (Figure S7).
Tourette syndrome PRS and Tic Severity
Given the strong enrichment of Tourette aPRS in cases from multiplex families, Tourette/ 
chronic tic family-history positive Tourette cases were next examined to test whether 
Tourette aPRS might serve as a predictor of higher disease severity in these cases 
(Supplemental Methods). Following adjustment for the first 4 GWAS principal components, 
higher Tourette aPRS was significantly correlated with increased worst-ever tic severity 
(β=0.93, SE=0.42, p=0.026), with every 1 SD increase in Tourette aPRS corresponding to a 
0.93 point increase in worst-ever tic severity (total range, 0-50).
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Tourette syndrome and Tic Spectrum Phenotypes
Given the hypothesis that Tourette and other tic disorders represent a phenotypic spectrum 
with a shared genetic etiology, Tourette PRS derived from the GWAS meta-analysis was 
compared in Tourette and tic spectrum cases in the Icelandic deCODE sample (Figure 2 and 
Figure S5). Tourette PRS was significantly higher in both deCODE Tourette syndrome cases 
and tic spectrum cases compared to controls (OR=1.33, p=5.3×10−9 and OR=1.20, p=5.2 
×10−4, respectively), explaining 0.78% and 0.42% of the phenotypic variance, respectively. 
Direct comparison between case groups confirmed that deCODE Tourette cases carried a 
higher Tourette syndrome polygenic burden than subjects with other tic spectrum disorders 
(OR=1.14, p=0.05), representing an excess 0.37% of the phenotypic variance (Figure 2).
Enrichment of Tourette syndrome heritability by functional annotation and gene 
expression
Tourette syndrome SNP-based heritability (h2g) from the GWAS meta-analysis was also 
used as a genome-wide probe to test whether aggregated Tourette syndrome genetic risk 
might be concentrated either in 52 specific functional genomic elements (e.g., promoters, 
enhancers, epigenetic marks) or in gene expression patterns from 10 grouped tissue/cell 
types using partitioned LDSC (22). Evolutionarily-conserved SNPs (2.6% of all SNPs) were 
enriched 16.5-fold for Tourette h2g, accounting for 42.3% of Tourette syndrome heritability 
(Pr(h2g)/Pr(SNPs)=16.5, SE=5.3, p=3.6×10−3, NS after correction). A parallel analysis 
including these evolutionarily-conserved SNPs plus 500-bp flanking windows (33% of all 
SNPs) was enriched 2.8-fold for Tourette h2g and accounted for 92.4% of Tourette syndrome 
heritability (Pr(hg2)/Pr(SNPs)=2.80, SE=0.46, p=1.0×10−4; p=0.005 after correction) (Figure 
S8). No other genomic annotations were significantly enriched for Tourette SNP-based 
heritability. In the cell-type analysis, significant enrichment was found only for CNS cell 
types, with 62.7% of Tourette syndrome heritability contributed by 14.8% of SNPs 
(p=4.2×10−8; p=4.2×10−7 after correction) (Figure S9).
Gene-based association and enrichment analyses
Gene-based association and enrichment tests were performed using meta-analysis summary 
statistics in MAGMA. FLT3 was identified with genome-wide significant association after 
correcting for 18,079 gene tests (p=8.9×10−7) (Figure S10). The most significant SNP in the 
FLT3 locus, rs2504235, was the only SNP surpassing genome-wide significance threshold in 
the primary meta-analysis, and was significantly associated with FLT3 expression level both 
in cerebellum (p=6.5×10−10) and cerebral cortex (p=2.6×10−11)(28). No gene set was 
significantly associated with Tourette syndrome after Bonferroni correction. In the gene 
expression enrichment analyses of 53 adult human tissues, only dorsolateral prefrontal 
cortex (Brodmann area 9 (BA9)) demonstrated significant enrichment of Tourette-associated 
genes after correction (β=0.023, SE=0.0069, p=1.2×10−4) (Figure 3, Supplemental 
Methods).
DISCUSSION
Tourette syndrome has long been conceptualized as part of a spectrum of developmental tic 
disorders, with transient tics at one end (1), and severe Tourette syndrome with multiple 
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psychiatric comorbidities at the other. However, until recently, potential biological 
relationships between the various tic disorders were unknown, as were the underlying 
genetic contributions to tic severity. The results of this study further illuminate the genetic 
architecture of Tourette syndrome and its relationships to phenotypic expression. First, the 
PRS analyses probing the genetic architecture of tic disorders in the population-based 
Icelandic sample demonstrates that individuals with Tourette syndrome share the same 
underlying polygenic risk as those with other tic disorders. Furthermore, the observation that 
Tourette syndrome cases have a significantly higher mean PRS than those with non-Tourette 
tic disorders provides evidence for a liability spectrum of genetic risk within tic disorders. 
Lastly, within Tourette syndrome cases, the finding that higher Tourette PRS was associated 
with increased tic severity also builds on our previous analyses demonstrating a relationship 
between higher Tourette PRS and the presence of complex symmetry and socially 
inappropriate tics (29). These relationships, although hypothesized based on clinical 
observations, have not previously been demonstrated at the molecular genetic level, and 
ultimately will help to provide insight into the molecular mechanisms of tic development 
and expression.
These observations have direct biological and clinical relevance. First, they support previous 
efforts to conceptualize Tourette and chronic tics as a unified condition and to combine them 
into a single tic spectrum disorder in future diagnostic schemas (1). Although traditionally 
separated clinically into distinct disorders, chronic/persistent tic disorders, whether 
consisting of motor tics, vocal tics, or both, appear to be due to the same underlying genetic 
causes. Second, while the small proportion of explained variance in worst-ever tic severity is 
a limitation of the current study, work in other polygenic psychiatric disorders such as 
schizophrenia has repeatedly demonstrated that, as GWAS sample sizes increase, the 
proportion of phenotype explained by polygenic risk scores increases markedly (30). It is 
therefore possible that in the future, Tourette PRS might be a potential candidate for 
predicting both conversion to chronic tics in the 20-25% of children who present with 
transient tics (1), and, at the other end of the phenotypic spectrum, tic persistence and 
lifetime tic severity in those with Tourette syndrome. Finally, particularly important in the 
context of the very large sample sizes required for the success of GWAS efforts, our results 
suggest that future genetic association studies may benefit from expanding disease 
definitions to include both Tourette and chronic tic cases.
Our genome-wide cell and tissue-based enrichment analyses implicate modulation of gene 
expression through non-coding variants as a fundamental mechanism in Tourette syndrome 
pathogenesis. All of the top tissues in the enrichment analyses were derived from brain, 
although dorsolateral pre-frontal cortex (BA9) was the only tissue in which eQTL 
enrichment surpassed Bonferroni correction. The 5 tissues with the strongest eQTL 
enrichment (frontal cortex, caudate, putamen, nucleus accumbens and cerebellum) all 
represent key nodes within the cortico-striatal and cortico-cerebellar circuits that have been 
implicated in Tourette pathophysiology (1). These results support the hypothesis that 
Tourette syndrome is a developmental circuit disorder affecting motor, cognitive and 
behavioral control (as manifested by tics, ADHD, and OCD symptoms), and suggest that 
future GWAS analyses in larger datasets should aid in identifying not only the individual 
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genes underlying Tourette syndrome susceptibility, but also core pathways in development 
and/or regulation of these circuits that could serve as targets for modulation-based therapies.
LIMITATIONS
This study has several potential limitations, the most significant of which is the sample size. 
Although the largest Tourette syndrome GWAS conducted to date, our sample of under 
5,000 cases is clearly not yet sufficient to identify definitive Tourette susceptibility variants, 
as demonstrated by the failure of the top GWAS SNP to replicate in the deCODE sample. 
Additional potential limitations are also related to sample size, including reduced power to 
examine additional clinical variables of interest such as age of onset of tics and co-occurring 
psychiatric illnesses such as obsessive compulsive disorder and attention deficit 
hyperactivity disorder. However, we anticipate that most, if not all, of these limitations can 
be resolved by substantial increases in the number of Tourette syndrome cases collected for 
GWAS, an effort that is currently underway.
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Figure 1. 
Results of the primary Tourette Syndrome GWAS meta-analysis of 4,819 cases and 9,488 
controls.
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Figure 2. 
Density plot demonstrating the distribution of Tourette syndrome polygenic risk scores 
(PRS) in population-based Icelandic Tourette cases (purple), tic disorder cases (blue), 
unscreened population controls (green), and tic negative population controls (orange).
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Figure 3. 
Gene expression enrichment analysis of genome-wide Tourette syndrome polygenic risk in 
53 adult human tissues.
Yu et al. Page 19
Am J Psychiatry. Author manuscript; available in PMC 2020 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Yu et al. Page 20
Ta
bl
e 
1.
To
p 
10
 li
nk
ag
e 
di
se
qu
ili
br
iu
m
 (L
D)
 in
de
pe
nd
en
t lo
ci 
in 
the
 pr
im
ary
 To
u
re
tte
 s
yn
dr
om
e 
G
W
A
S 
m
et
a-
an
al
ys
is.
SN
P
C
H
R
BP
A
1/
A
2
Pr
im
ar
y 
m
et
a-
an
al
ys
is
de
C
O
D
E
Pr
im
ar
y 
+ 
de
C
O
D
E
LD
 b
lo
ck
G
EN
ES
G
W
A
S 
ca
ta
lo
g
IN
FO
FR
Q
O
R
P
FR
Q
O
R
P
O
R
P
rs
25
04
23
5
13
28
,6
12
,8
86
A
/G
0.
99
0.
38
1.
16
2.
1E
-0
8
0.
32
0.
94
0.
50
1.
14
2.
4E
-0
7
28
59
13
18
..2
86
59
47
3
FL
T3
rs
19
10
44
31
0
10
23
,7
05
,4
51
A
/T
0.
83
0.
02
0.
54
1.
5E
-0
7
0.
00
24
2.
27
0.
25
0.
56
5.
9E
-0
7
23
66
11
49
..2
38
15
12
0
OT
U
D
1
rs
13
40
72
15
2
16
1,
54
4,
89
1
T/
C
1.
00
0.
02
2.
21
1.
9E
-0
7
0.
00
01
0.
02
0.
85
2.
21
1.
9E
-0
7
16
00
90
84
4.
.1
62
91
24
53
A
H
CT
F1
P1
,B
A
Z2
B,
CD
30
2,
D
PP
4,
IT
G
B6
,L
O
C6
43
 0
72
,L
O
C1
00
50
59
84
,L
O
C1
00
99
65
79
,L
O
C1
01
9 
29
51
2,
LY
75
,L
Y
75
-C
D
30
2,
M
A
RC
H
7,
M
IR
47
85
,P
LA
2R
1,
PS
M
D
14
,R
BM
S1
,S
LC
4A
10
,T
A
N
C1
,T
A
N
K
,T
BR
1,
W
D
SU
B1
rs
27
08
14
6
2
58
95
59
53
G
/A
1.
00
9
0.
46
0.
88
3.
2E
-0
7
0.
48
0.
98
0.
75
0.
89
8.
0E
-0
7
58
84
79
53
..5
90
94
60
9
LI
N
C0
11
22
rs
19
06
25
2
6
98
,5
50
,2
89
A
/C
1.
00
0.
49
0.
88
7.
0E
-0
7
0.
50
0.
90
0.
17
0.
88
2.
8E
-0
7
98
21
48
14
..9
86
64
41
4
M
IR
21
13
B
ip
ol
ar
 d
iso
rd
er
,
 
Ed
uc
at
io
na
l a
tta
in
m
en
t, 
G
ut
 m
ic
ro
bi
ot
a,
 
In
te
lli
ge
nc
e
rs
12
45
95
60
19
52
,3
18
,3
80
T/
G
0.
98
0.
15
1.
19
8.
2E
-0
7
0.
16
1.
08
0.
45
1.
18
9.
1E
-0
7
52
26
60
72
..5
26
06
93
6
FP
R
1,
FP
R2
,F
PR
3,
H
CC
AT
3,
LO
C1
01
92
85
71
,Z
N
F3
50
,Z
N
F4
32
,Z
N
F5
77
,Z
N
F6
13
,Z
N
F6
14
,Z
N
F6
15
,Z
N
F6
16
,Z
N
F6
49
,Z
N
F8
41
rs
11
76
48
88
1
8
11
3,
58
1,
89
8
A
/G
0.
77
0.
02
0.
59
8.
8E
-0
7
0.
01
0.
72
0.
32
0.
60
6.
2E
-0
7
11
35
81
89
8.
.1
14
61
29
03
CS
M
D
3,
M
IR
20
53
rs
66
70
21
1
1
29
,5
76
,7
84
A
/C
1.
00
0.
47
0.
88
1.
4E
-0
6
0.
42
0.
94
0.
45
0.
89
1.
5E
-0
6
29
18
86
30
..2
96
07
27
9
EP
B
41
,M
EC
R,
O
PR
D
1,
PT
PR
U
,S
RS
F4
,T
M
EM
20
0B
rs
72
85
33
20
6
36
,6
23
,3
38
A
/G
1.
00
0.
13
1.
20
1.
7E
-0
6
0.
12
0.
88
0.
28
1.
17
2.
2E
-0
5
36
37
59
86
..3
66
58
09
2
CD
K
N
1A
,K
CT
D
20
,M
IR
39
25
,P
A
N
D
A
R,
PX
T1
,R
A
B4
4,
SR
SF
3,
ST
K
38
rs
73
20
54
93
4
2,
46
0,
57
1
T/
C
0.
89
0.
34
1.
16
1.
8E
-0
6
0.
35
1.
08
0.
34
1.
15
1.
6E
-0
6
24
07
26
3.
.2
48
10
88
LO
C4
02
16
0,
RN
F4
,Z
FY
V
E2
8
Am J Psychiatry. Author manuscript; available in PMC 2020 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Yu et al. Page 21
Table 2.
Single nucleotide polymorphism (SNP)-based heritability estimates for the Tourette syndrome GWAS1 and 
GWAS2 European ancestry case-control samples.
Samplea Cases(%) Controls (%) V(G)/Vp_Lc SE P
GWAS1 559 (14%) 3400 (86%) 0.565 0.096 1.2×10−9
GWAS2b 2146 (46%) 2564 (54%) 0.288 0.040 5.5×10−14
GWAS2b web-based 934 (27%) 2564 (73%) 0.294 0.067 2.4×10−6
GWAS2b clinic-based 1098 (30%) 2564 (70%) 0.284 0.059 4.0×10−7
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